XML 48 R2.htm IDEA: XBRL DOCUMENT v3.26.1
Pay vs Performance Disclosure
 12 Months Ended
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Pay vs Performance Disclosure          
Pay vs Performance Disclosure, Table
Value of Initial Fixed $100 Investment based on:(3)
Year
Summary Compensation Table Total for First PEO(1)
Compensation Actually Paid to First PEO(1)(2)
Summary Compensation Table Total for Second PEO(1)
Compensation Actually Paid to Second PEO(1)(2)
Average Summary Compensation Table Total for Non-PEO NEOs(1)
Average Compensation Actually Paid to Non-PEO NEOs(1)(2)
Total Shareholder ReturnPeer Group Total Shareholder ReturnNet (Loss) Income (millions)
Adjusted EBITDA %(4)
2025$— $— $10,559,567 $14,254,917 $2,350,132 $2,832,791 $64 $136 $47.0 13.7 %
2024$8,916,147 $4,211,172 $23,825,973 $22,798,643 $2,374,526 $1,830,036 $57 $121 $(1,118.6)11.8 %
2023$7,059,325 $(1,816,558)$— $— $1,675,659 $(222,491)$71 $120 $(100.2)18.1 %
2022$8,523,732 $(4,535,253)$— $— $1,836,308 $(42,128)$100 $120 $243.1 20.1 %
2021$9,199,748 $28,844,127 $— $— $2,474,388 $4,661,522 $134 $124 $340.5 19.7 %
        
Company Selected Measure Name adjusted EBITDA        
Named Executive Officers, Footnote The First PEO until May 1, 2024 and for 2023, 2022 and 2021 was Amir Aghdaei. The Second PEO beginning May 1, 2024 and for 2025 was Paul Keel. The non-PEO NEOs for 2022 and 2021 were Howard Yu (Senior Vice President and Chief Financial Officer), Jean-Claude Kyrillos (Senior Vice President of Diagnostics), Patrik Eriksson (Senior Vice President, President of Nobel Biocare), and Mark Nance (Senior Vice President, General Counsel and Secretary). The non-PEO NEOs for 2023 were Mr. Yu, Mr. Kyrillos, Mr. Eriksson, Mr. Nance, Stephen Keller (Principal Financial Officer) and Eric Conley (Senior Vice President and President, Orthodontics). The non-PEO NEOs for 2024 were Mr. Hammes, Mr. Nance, Mr. Befidi Mr. Reis, and Mr. Keller.        
Peer Group Issuers, Footnote Total shareholder return (“TSR”) is determined based on the value of an initial fixed investment of $100 on December 31, 2020. The Peer Group TSR set forth in this table utilizes the S&P 500 Health Care Index, which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K included in our Annual Report on Form 10-K for the year ended December 31, 2025. Historical stock performance is not necessarily indicative of future stock performance.        
Adjustment To PEO Compensation, Footnote
Equity award adjustments
YearExecutive(s)SCT TotalDeduct grant date fair value of equity awards reported in SCTAdd year-end value of unvested equity awards granted in yearChange in value of unvested equity awards granted in prior yearsFair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the YearChange in value of equity awards granted in prior years which vested in year
2025PEO$10,559,567 $(6,800,197)$9,139,533 $1,553,693 $— $(197,679)
Non-PEO NEOs$2,350,132 $(1,125,174)$1,448,541 $129,311 $— $29,982 
2024First PEO$8,916,147 $(5,500,191)$2,723,931 $(1,018,457)$— $(910,258)
Second PEO $23,825,973 $(21,400,169)$20,372,839 $(4,218,279)$— $4,218,279 
Non-PEO NEOs$2,374,526 $(1,399,382)$1,010,312 $(80,640)$(31,917)$(42,863)
2023PEO$7,059,325 $(5,200,178)$1,613,810 $(5,825,994)$— $536,479 
Non-PEO NEOs$1,675,659 $(971,147)$212,290 $(332,625)$(891,449)$84,781 
2022PEO$8,523,732 $(5,100,321)$2,608,474 $(11,166,139)$— $599,000 
Non-PEO NEOs$1,836,308 $(1,025,211)$537,397 $(1,446,374)$— $55,752 
2021PEO$9,199,748 $(4,700,022)$6,694,551 $14,514,792 $— $3,135,059 
Non-PEO NEOs$2,474,388 $(1,350,182)$2,029,238 $1,321,927 $— $186,151 
        
Non-PEO NEO Average Total Compensation Amount $ 2,350,132 $ 2,374,526 $ 1,675,659 $ 1,836,308 $ 2,474,388
Non-PEO NEO Average Compensation Actually Paid Amount $ 2,832,791 1,830,036 (222,491) (42,128) 4,661,522
Adjustment to Non-PEO NEO Compensation Footnote
Equity award adjustments
YearExecutive(s)SCT TotalDeduct grant date fair value of equity awards reported in SCTAdd year-end value of unvested equity awards granted in yearChange in value of unvested equity awards granted in prior yearsFair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the YearChange in value of equity awards granted in prior years which vested in year
2025PEO$10,559,567 $(6,800,197)$9,139,533 $1,553,693 $— $(197,679)
Non-PEO NEOs$2,350,132 $(1,125,174)$1,448,541 $129,311 $— $29,982 
2024First PEO$8,916,147 $(5,500,191)$2,723,931 $(1,018,457)$— $(910,258)
Second PEO $23,825,973 $(21,400,169)$20,372,839 $(4,218,279)$— $4,218,279 
Non-PEO NEOs$2,374,526 $(1,399,382)$1,010,312 $(80,640)$(31,917)$(42,863)
2023PEO$7,059,325 $(5,200,178)$1,613,810 $(5,825,994)$— $536,479 
Non-PEO NEOs$1,675,659 $(971,147)$212,290 $(332,625)$(891,449)$84,781 
2022PEO$8,523,732 $(5,100,321)$2,608,474 $(11,166,139)$— $599,000 
Non-PEO NEOs$1,836,308 $(1,025,211)$537,397 $(1,446,374)$— $55,752 
2021PEO$9,199,748 $(4,700,022)$6,694,551 $14,514,792 $— $3,135,059 
Non-PEO NEOs$2,474,388 $(1,350,182)$2,029,238 $1,321,927 $— $186,151 
        
Compensation Actually Paid vs. Total Shareholder Return
Description of Relationship Between PEO and Other NEO Compensation Actually Paid, Company TSR, and Peer Group TSR

The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our other NEOs, the Company’s cumulative TSR over the five most recently completed fiscal years, and the TSR of the S&P 500 Health Care Index over the same period.
        
Compensation Actually Paid vs. Net Income
PvP - Comp Actual vs TSR.jpg

Description of Relationship Between PEO and Other NEO Compensation Actually Paid and Net Income

The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our other NEOs, and our Net Income during the five most recently completed fiscal years.

PvP - Comp Actual vs Net Income.jpg
        
Compensation Actually Paid vs. Company Selected Measure
Description of Relationship Between PEO and Other NEO Compensation Actually Paid and Adjusted EBITDA Margin

The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our other NEOs, and our adjusted EBITDA margin during the five most recently completed fiscal years.

PvP - Comp Actual vs Adj. EBITDA.jpg
        
Total Shareholder Return Vs Peer Group
Description of Relationship Between PEO and Other NEO Compensation Actually Paid, Company TSR, and Peer Group TSR

The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our other NEOs, the Company’s cumulative TSR over the five most recently completed fiscal years, and the TSR of the S&P 500 Health Care Index over the same period.
        
Tabular List, Table
•Core Sales Growth
•Free Cash Flow
•Adjusted EBITDA Margin
        
Total Shareholder Return Amount $ 64 57 71 100 134
Peer Group Total Shareholder Return Amount 136 121 120 120 124
Net Income (Loss) $ 47,000,000.0 $ (1,118,600,000) $ (100,200,000) $ 243,100,000 $ 340,500,000
Company Selected Measure Amount 0.137 0.118 0.181 0.201 0.197
Additional 402(v) Disclosure The amounts shown in the Compensation Actually Paid columns have been calculated in accordance with Item 402(v) of Regulation S-K and do not reflect compensation actually earned, realized, or received by the Company’s NEOs. These amounts reflect the Summary Compensation Table (“SCT”) Total with certain adjustments as described below.        
Measure:: 1          
Pay vs Performance Disclosure          
Name Core Sales Growth        
Measure:: 2          
Pay vs Performance Disclosure          
Name Free Cash Flow        
Measure:: 3          
Pay vs Performance Disclosure          
Name Adjusted EBITDA Margin        
Non-GAAP Measure Description We determined adjusted EBITDA margin, calculated consistent with how the Company reports adjusted EBITDA to the public, divided by the Company’s total net sales, to be the most important financial performance measure used to link Company performance to Compensation Actually Paid to our PEO and Non-PEO NEOs in 2025.        
Paul Keel [Member]          
Pay vs Performance Disclosure          
PEO Total Compensation Amount $ 10,559,567 $ 23,825,973      
PEO Actually Paid Compensation Amount $ 14,254,917 $ 22,798,643      
PEO Name Paul Keel. Paul Keel.      
Amir Aghdaei [Member]          
Pay vs Performance Disclosure          
PEO Total Compensation Amount   $ 8,916,147 $ 7,059,325 $ 8,523,732 $ 9,199,748
PEO Actually Paid Compensation Amount   $ 4,211,172 $ (1,816,558) $ (4,535,253) $ 28,844,127
PEO Name   Amir Aghdaei Amir Aghdaei Amir Aghdaei Amir Aghdaei
PEO | Paul Keel [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount $ (6,800,197) $ (21,400,169)      
PEO | Paul Keel [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 9,139,533 20,372,839      
PEO | Paul Keel [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 1,553,693 (4,218,279)      
PEO | Paul Keel [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (197,679) 4,218,279      
PEO | Amir Aghdaei [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount   (5,500,191) $ (5,200,178) $ (5,100,321) $ (4,700,022)
PEO | Amir Aghdaei [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount   2,723,931 1,613,810 2,608,474 6,694,551
PEO | Amir Aghdaei [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount   (1,018,457) (5,825,994) (11,166,139) 14,514,792
PEO | Amir Aghdaei [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount   (910,258) 536,479 599,000 3,135,059
Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (1,125,174) (1,399,382) (971,147) (1,025,211) (1,350,182)
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 1,448,541 1,010,312 212,290 537,397 2,029,238
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 129,311 (80,640) (332,625) (1,446,374) 1,321,927
Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount $ 29,982 (42,863) 84,781 $ 55,752 $ 186,151
Non-PEO NEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount   $ (31,917) $ (891,449)